Lilly joins with Chinese biotech to develop, market cancer drugs

Eli Lilly agrees to form one of the broadest collaborations to date between a large Western drug maker and a Chinese biotechnology company, a sign of the pharmaceutical industry’s interest in the Chinese market despite recent growing pains.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.